CONTEXT
Public and private financial support of biomedical research have increased over the past decade. Few comprehensive analyses of the sources and uses of funds are available. This results in inadequate information on which to base investment decisions because not all sources allow equal latitude to explore hypotheses having scientific or clinical importance and creates a barrier to judging the value of research to society.
OBJECTIVE
To quantify funding trends from 1994 to 2004 of basic, translational, and clinical biomedical research by principal sponsors based in the United States.
DESIGN
Publicly available data were compiled for the federal, state, and local governments; foundations; charities; universities; and industry. Proprietary (by subscription but openly available) databases were used to supplement public sources.
MAIN OUTCOME MEASURES
Total actual research spending, growth rates, and type of research with inflation adjustment.
RESULTS
Biomedical research funding increased from 37.1 billion dollars in 1994 to 94.3 billion dollars in 2003 and doubled when adjusted for inflation. Principal research sponsors in 2003 were industry (57%) and the National Institutes of Health (28%). Relative proportions from all public and private sources did not change. Industry sponsorship of clinical trials increased from 4.0 dollars to 14.2 billion dollars (in real terms) while federal proportions devoted to basic and applied research were unchanged. The United States spent an estimated 5.6% of its total health expenditures on biomedical research, more than any other country, but less than 0.1% for health services research. From an economic perspective, biotechnology and medical device companies were most productive, as measured by new diagnostic and therapeutic devices per dollar of research and development cost. Productivity declined for new pharmaceuticals.
CONCLUSIONS
Enhancing research productivity and evaluation of benefit are pressing challenges, requiring (1) more effective translation of basic scientific knowledge to clinical application; (2) critical appraisal of rapidly moving scientific areas to guide investment where clinical need is greatest, not only where commercial opportunity is currently perceived; and (3) more specific information about sources and uses of research funds than is generally available to allow informed investment decisions. Responsibility falls on industry, government, and foundations to bring these changes about with a longer-term view of research value.
[1]
Christopher Martyn.
What Price Better Health? Hazards of the Research Imperative
,
2004,
BMJ : British Medical Journal.
[2]
Andrew A. Signore,et al.
Pharmaceutical Industry Profile
,
2005
.
[3]
R. F. Jones,et al.
Clinical revenues used to support the academic mission of medical schools, 1992‐93
,
1996,
Academic medicine : journal of the Association of American Medical Colleges.
[4]
Walter W. Powell,et al.
A Comparison of U.S. and European University-Industry Relations in the Life Sciences
,
2001
.
[5]
Fredric J Cohen.
What ails the FDA?
,
2005,
The New England journal of medicine.
[6]
Margaret O'Mara.
Cities of Knowledge: Cold War Science and the Search for the Next Silicon Valley
,
2005
.
[7]
Jerry Harris.
US
,
2000
.
[8]
Ralph Landau.
chapter four – THE INNOVATIVE MILIEU
,
1982
.
[9]
E. Campbell,et al.
Market forces and unsponsored research in academic health centers.
,
1999,
JAMA.
[10]
R. Rosenberg.
Translating biomedical research to the bedside: a national crisis and a call to action.
,
2003,
JAMA.
[11]
H. Moses,et al.
Why have academic medical centers survived
,
2005
.
[12]
D. Commerce.
Statistical abstract of the United States
,
1978
.
[13]
U. C. Bureau.
Statistical Abstract of the United States
,
2004
.
[14]
L. Kohn,et al.
To Err Is Human : Building a Safer Health System
,
2007
.
[15]
Linet Özdamar,et al.
International comparison of health care systems
,
2004
.
[16]
E. McGlynn,et al.
How good is the quality of health care in the United States?
,
1998,
The Milbank quarterly.
[17]
M. Osterholm,et al.
Preparing for the next pandemic.
,
2005,
The New England journal of medicine.
[18]
C. Marano,et al.
To err is human. Building a safer health system
,
2005
.
[19]
H. Moses,et al.
Why have academic medical centers survived?
,
2005,
JAMA.
[20]
M. Buxton,et al.
Estimating the economic value to societies of the impact of health research: a critical review.
,
2004,
Bulletin of the World Health Organization.